key: cord-0307208-wm3wtw62 authors: Nguyen, T. P.; Do, Q.; Lan, L. T.; Dinh, D. V.; Khong, H.; Do, S. M. title: Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine date: 2021-07-25 journal: nan DOI: 10.1101/2021.07.22.21260942 sha: 4981658bc3abb4f2a320f0ab1043e7963e49b69c doc_id: 307208 cord_uid: wm3wtw62 Background Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminum hydroxide adjuvant. Methods We conducted a dose-escalation, open label trial (phase 1) and a randomized, double-blind, placebo-controlled trial (phase 2) to evaluate the safety and immunogenicity of the Nanocovax vaccine (in 25 microgram (mcg), 50 mcg, and 75 mcg doses, aluminum hydroxide adjuvanted). In phase 1, 60 participants received two intramuscular injection of the vaccine following dose-escalation procedure. The primary outcomes were reactogenicity and laboratory tests to evaluate the vaccine safety. In phase 2 which involved in 560 healthy adults, the primary outcomes are vaccine safety; and anti-S IgG antibody response. Secondary outcomes were surrogate virus neutralization, wild-type SARS-CoV-2 neutralization, and T-cell responses by intracellular staining (ICS) for interferon gamma (IFNg). We performed primary analyses at day 35 and day 42. Results For phase 1 study, no serious adverse events (SAE) were observed for all 60 participants. Most adverse events (AE) were grade 1 and disappeared shortly after injection. For phase 2 study, after randomization, 480 participants were assigned to receive the vaccine with adjuvant, and 80 participants were assigned to receive placebo. Reactogenicity was absent or mild in the majority of participants and of short duration (mean, [≤]3 days). Unsolicited adverse events were mild in most participants. There were no serious adverse events related to Nanocovax. Regarding the immunogenicity, Nanocovax induced robust anti-S antibody responses. There was no statistical difference in antibody responses among dose strengths on Day 42, in terms of anti S-IgG level and neutralizing antibody titer. Conclusions Up to 42 days, Nanocovax vaccine was safe, well tolerated and induced robust immune responses. We propose using Nanocovax 25 mcg for Phase 3 to evaluate the vaccine efficacy. (Research funded by Nanogen Pharmaceutical Biotechnology JSC., and the Ministry of Science and Technology of Vietnam; ClinicalTrials.gov number, NCT04683484.) vaccine (in 25 microgram (mcg), 50 mcg, and 75 mcg doses, aluminum hydroxide adjuvanted). In phase 1, 60 participants received two intramuscular injection of the vaccine following doseescalation procedure. The primary outcomes were reactogenicity and laboratory tests to evaluate the vaccine safety. In phase 2 which involved in 560 healthy adults, the primary outcomes are vaccine safety; and anti-S IgG antibody response. Secondary outcomes were surrogate virus neutralization, wild-type SARS-CoV-2 neutralization, and T-cell responses by intracellular staining (ICS) for interferon gamma (IFNg). We performed primary analyses at day 35 and day 42. For phase 1 study, no serious adverse events (SAE) were observed for all 60 participants. Most adverse events (AE) were grade 1 and disappeared shortly after injection. For phase 2 study, after randomization, 480 participants were assigned to receive the vaccine with adjuvant, and 80 participants were assigned to receive placebo. Reactogenicity was absent or mild in the majority of participants and of short duration (mean, ≤3 days). Unsolicited adverse events were mild in most participants. There were no serious adverse events related to Nanocovax. Regarding the immunogenicity, Nanocovax induced robust anti-S antibody responses. There was no statistical difference in antibody responses among dose strengths on Day 42, in terms of anti S-IgG level and neutralizing antibody titer. Up to 42 days, Nanocovax vaccine was safe, well tolerated and induced robust immune responses. We propose using Nanocovax 25 mcg for Phase 3 to evaluate the vaccine efficacy. (Research funded by Nanogen Pharmaceutical Biotechnology JSC., and the Ministry of Science and Technology of Vietnam; ClinicalTrials.gov number, NCT04683484.) Global pandemic coronavirus disease 2019 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of July 2021, more than 177 million cases and over 4 million deaths due to Covid-19 have been reported worldwide 1 . SARS-CoV-2 is a member betacoronavirus, named for its corona of spike (S) proteins protruding from the viral envelope 2,3 . SARS-CoV-2 S, a heavily glycosylated protein, is responsible for the attachment to angiotensin-converting enzyme (ACE2) which helps the virus entry to host cells in human and animals 4 . SARS-CoV-2 S glycoprotein is the antigen of choice for Covid-19 vaccine development due to its highly antigenic property 5 . Nanocovax is a subunit vaccine, developed and manufactured at Nanogen Pharmaceutical Biotechnology JSC., containing full-length prefusion stabilized recombinant SARS-CoV-2 S glycoproteins and aluminum hydroxide adjuvant. In rodent and monkey models, Nanocovax induced high levels of anti-S antibody (Ab). Neutralizing antibody titers were evaluated by microneutralization on Wuhan strain and surrogate virus neutralization test. Importantly, Nanocovax conferred a remarkable protection against SARS-CoV-2 infection in hamster challenge model 6 . Here we report the findings of the phase 1 and 2 trials started in December 2020 and February 2021 respectively, to evaluate the safety and immunogenicity of 25 mcg, 50 mcg and 75mcg dose strengths of recombinant SARS-CoV-2 S glycoprotein with aluminum adjuvant (0.5 mg/dose) in healthy adults of at least 18 years of age. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. participants in 75 µg dose group, the remaining participants in this group will be vaccinated. Accordingly, a total of 560 participants will be randomly assigned to 4 groups, into 2:2:2:1 ratio for 25 µg, 50 µg, 75 µg, and placebo, respectively. In details, 480 volunteers would receive the vaccine (160 volunteers receiving 25 µg dose; 160 volunteers receiving 50 µg dose and 160 volunteers receiving dose of 75 µg dose) and 80 volunteers would receive the placebo (aluminum adjuvant only). All participants received 2 intramuscular injections of the vaccine or the placebo into the deltoid on day 0 and day 28. Trial staffs responsible for the vaccine preparation and administration, and participants were unaware of vaccine assignment. Randomization lists, using block randomization stratified by study group and study site, were generated by the study statistician. Computer randomization was done with full allocation concealment within the secure web platform used for the study electronic case report form (service provided by Medprove company). All participants were screened by their medical history, clinical and biological examinations, sampling and laboratory tests (complete blood count, biochemistry, urine analysis, testing pregnancy and diagnostic imaging). Participants with a history of Covid-19 or positive results for SARS-CoV-2 at screening period confirmed by real-time reverse transcriptase polymerase-chain-reaction (RT-PCR) were excluded from the trials. All participants provided written consent before being enrolled into the trial. The recombinant SARS-CoV-2 spike (S) glycoprotein in Nanocovax were constructed with 682-QQAQ-685 mutations for protease resistance, and two proline substitutions (K986P and V987P) for stabilized prefusion conformation. The production of the full-length (including the transmembrane domain) recombinant S protein was optimized in the established Chinese Hamster Ovary (CHO) cell-expression system. Clinical grade aluminum hydroxide was manufactured by Croda (Denmark). Recombinant SARS-CoV-2 S protein were absorbed to aluminum adjuvant in mild shaking condition for 18 hours at 2°C to 8°C. Placebo was sterile 0.05% aluminum. In phase 1, the onsite safety follow-up time after was 72 hours after 1 st injection and 24 hours after the 2 nd injection. Participants would return to the study site for follow-up visits at scheduled timepoints (table S1). In phase 2, the onsite safety follow-up time was 60 minutes after each vaccination. Follow-up visits to evaluate safety were scheduled on days 28, 35, 42, 90, 180 after vaccination (table 1) . Participants were observed for 60 minutes after each vaccination for assessment of reactogenicity. In both phases, participants received instruction for self-monitoring and reporting adverse events during 7 days after each vaccination, as All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2021. The primary outcome was anti-S IgG responses to Nanocovax evaluated by chemiluminescence immunoassay (CLIA). Secondary outcomes were neutralizing antibody titer evaluated by 50 percent plaque reduction neutralization test (PRNT50) on Wuhan strain and UK variant (B.1.1.7), neutralizing activity evaluated by competitive enzyme-linked immunosorbent assay (ELISA) based surrogate virus neutralization test (sVNT), and T cell response by intracellular cytokine-staining (ICS). Details of these assays are provided in the supplementary appendix. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Local and systemic adverse events occurred during 7 days after each injection were documented (number, percentage) by group (vaccine and placebo) and analyzed to find factors (if any) correlated/associated with the severity of AE. Serious adverse events were classified according to CTCAE 5.0 and statistically described according to the number and percentage of each research group. If an adverse event occurs more than once, analysis is based on only the most severe occurrence and the cause of the event. In addition, all serious adverse events will be summarized separately. The results were statistically described as number of and percentage of volunteers having abnormal results or have results changed overtime, by group, compared to baseline values. Values higher than normal ranges/thresholds will be assessed for clinical significance by researchers. AE/SAEs were statistically analyzed the difference in percentage cumulative with 95% confidence interval of the Clopper-Pearson method (Clopper-Pearson 95% CIs) between vaccine dose groups. The (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In phase 1, no serious adverse events were observed, and vaccination pause rules were not implemented. Overall reactogenicity was largely absent or mild, and second vaccinations were neither withheld nor delayed due to reactogenicity. The percentage of participants in each vaccine group (groups 1.1, 1. The incidence of unsolicited AEs in were similar in vaccine groups and the placebo (appendix 7). In details, unsolicited AE incidence of groups 2.1 to 2.4 were 30.4%, 27.5%, 23.3% and 33.8%, respectively. Two cases of grade 4 AE were back pain and dizziness. There were five AE of grade 3: 1 case of sepsis, 1 case of back pain, 1 case of spondylolisthesis, 1 case of sore throat, 1 case of high blood pressure. The most frequently reported adverse events were sore throat 27 (4.8%) and coughing 11 (2%). The most laboratory-related AEs were hyperglycemia 13 cases (2.3%), leukocytosis: 8 cases (1.4%), the most vital events related to hypothermia with 12 cases (2.1%). In similar to phase 1, vaccination pause rules were not implemented in phase 2. Four SAE were determined unrelated to Nanocovax, including 1 case of angina (history of stent graft), 1 case of fever (determined to be sepsis), 1 case of abscess at axillary lymph nodes occurred on the unvaccinated arm and 1 case of personal injury. One case All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Moderate sensitivity accounted for 4% (22/556) after injection 1 and 3.8% (21/554) after injection 2. The severe event (grade 3) was "pain at injection site" appearing in 1 subject after 2nd injection, accounting for 0.2% (1/554) and "redness at injection site" occurring in 2 subjects (2/554) after 2nd injection. The events mostly occurred within 2 days after vaccination, gradually decreased and disappeared within 7 days after vaccination. Some subjects felt fatigue after injection, accounting for 9.4% (52/556) after 1st injection and 8.3% (46/554) after 2nd injection. Fatigue decreased gradually day by day, disappeared at about 7 days after injection. The event "fever" occurred in relatively few subjects, mild fever accounted for 0.2% (1/556) after 1st injection and 1.1% (6/554) after 2nd injection. There was 1 subject with high fever (grade 3) accounted for 0.2% (1/556), occurred from day 1 to day 5 after 2nd injection. In the phase 2 study, the proportion of subjects with any "unsolicited" AE after injection with vaccine and placebo was 157/560 (28%). The rates of any AE in the study groups were similar between the 25 mcg (30.4%), 50 mcg (27.5%), 75 mcg (23.3%) and placebo (33.8%) groups. Most of "unsolicited" AEs were mild to moderate. When comparing the overall incidence of unsolicited AEs between the vaccine and placebo groups, the rates were similar in the two groups, with a ratio of 130/480 (27.1%) in the vaccinated group compared to the ratio of 27/80 (33.8%) in the placebo group. Laboratory abnormalities in phase 2 included increased white blood cell in 3 participants, (0.6%), increased neutrophil in 2 participants (0.4%), elevated ALT (grade 2) in 3 participants (0.6%), and elevated AST (grade 2) in 2 participants (0.4%). The other biochemistry and hematology parameters such as red blood cell (RBC), hemoglobin (HGB), creatinine, bilirubin, prothrombin time (PT) fluctuated within normal limits (appendix 7). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260942 doi: medRxiv preprint Anti-S IgG antibody in the serum was quantified by CLIA. Geometric mean concentration (GMC) of anti-S IgG (U/ml) was reported. Before the first injection, the GMC values of the 4 groups were all below the lower limit of detection. Anti-S IgG GMC of 3 vaccine groups increased sharply after 2nd injection, on day 35 and day 42 ( figure 3) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. T cell responses of 84 randomly selected participants (28 for each vaccine group and 14 for placebo group) were undetectable (data not shown). This was likely due to the nature of aluminum adjuvant which has been well established for Th2 response induction. The results of these phase 1 and phase 2 studies demonstrated an excellent safety profile of Nanocovax, regardless of dose strengths. Most adverse events and serious adverse events were grade 1 which disappeared within 48 hours after injection. Compared to similar studies of other approved vaccines, the vaccine may have the least reactogenicity 10-16 . The vaccine was found to elicit high level of anti-S IgG which closely correlated with neutralizing antibody levels (figure S8). Importantly, PRNT results showed that the vaccine, regardless of dose strength, was effective against both original Wuhan strain and UK variant (B.1.1.7) ( figure 4B and figure S7 ). Cellular immune response, evaluated by ICS for IFNg, was not observable. However, undetectable IFNg signal, a marker of Th1 response, does not guarantee the absence T cell response. In fact, it was likely due to the Th2 promoting nature of aluminum adjuvant 17 . Accordingly, T cell responses will be reevaluated in a small subset of participants in phase 3 with the addition of Th2 cytokines. The Th2 responses, if detected in phase 3, may raise a theoretical concern for vaccine-associated enhanced respiratory disease (ERD) 18, 19 . This concern has been partially addressed with the aforementioned SARS-CoV-2 challenge on hamster model 6 . We will further evaluate the risk of ERD in phase 3 trial. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 25, 2021. ; Although the efficacy of Nanocovax remains to be seen in a phase 3 trial, accumulated evidences have correlated the immunogenicity, particularly the neutralizing antibody level with the protection against Covid-19. Khoury Limitations of these phase 1 and 2 trials are limited ethnic diversity (almost exclusively Vietnamese Kinh people), short follow-up duration, healthy participants only and the lack of convalescent serum data. Without comparison of vaccine responses to convalescent sera from covid-19 patients, it is difficult to compare and contrast the immunogenicity of different vaccines and hence the projected efficacy. This shortcoming will be addressed in phase 3 trial. In conclusion, Nanocovax is highly safe and immunogenic. Dose strength of 25 mcg is selected for phase 3 to evaluate the vaccine efficacy. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. COVID Live Update: 190,075,727 Cases and 4,087,371 Deaths from the Coronavirus -Worldometer How Genomic Information has been Used to Deal with Past Outbreaks and the COVID-19 Pandemic Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Site-specific glycan analysis of the SARS-CoV-2 spike Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 PRE-CLINICAL IMMUNE RESPONSE AND SAFETY EVALUATION OF THE PROTEIN SUBUNIT VACCINE NANOCOVAX FOR COVID-19 Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Aluminum adjuvants: preparation, application, dosage, and formulation with antigen A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Vaccination X X During the study Table 2 Demographic characteristics of the participants in the phase 2 trial at enrollment.